Effect of Intravitreal Ranibizumab Injection on Introcular Pressure

There was no significant difference among intraocular pressure values measured before and after the injections.Conclusion: Although intravitreal ranibizumab injection has no effect on intraocular pressure, few cases may have increased intraocular pressure.

📌 3 Key Takeaways

🎯

Objective & Hypothesis:Purpose: To investigate the effect of ranibizumab a vascular endothelial growth factor inhibitor - on intraocular pressure.Material and Methods: Records of sixty-one eyes of 56 patients received intravitreal ranibizumab injection due to exudative age-related macular degeneration were investigated, retrospectively.

📊

Key Findings & Data:Intraocular pressures measured 1 day, 1, 3 and 6 months after the injection were evaluated.

💡

Conclusion & Impact:There was no significant difference among intraocular pressure values measured before and after the injections.Conclusion: Although intravitreal ranibizumab injection has no effect on intraocular pressure, few cases may have increased intraocular pressure.

🔬Design:Research Article

📍Scope:Comprehensive Sample

⚙️Variables:Domain Parameters

Abstract

Purpose: To investigate the effect of ranibizumab a vascular endothelial growth factor inhibitor - on intraocular pressure.Material and Methods: Records of sixty-one eyes of 56 patients received intravitreal ranibizumab injection due to exudative age-related macular degeneration were investigated, retrospectively. Intraocular pressures measured 1 day, 1, 3 and 6 months after the injection were evaluated. There was no significant difference among intraocular pressure values measured before and after the injections.Results: The mean age of the patients was 72.6±7.5. Sixty one eye received intravitreal ranibizumab injection. The followup duration was 6 months. all the patients had intraocular pressure lower than 21 mmHg at first dat after the injection. At first month and third month, there was only one patient having intraocular pressure higher than 21 mmHg. . There was no significant difference among intraocular pressure values measured before and after the injections.Conclusion: Although intravitreal ranibizumab injection has no effect on intraocular pressure, few cases may have increased intraocular pressure.

Özet

Amaç: Vasküler endotelyal büyüme faktör inhibitörü ranibizumabın göz içi basıncına etkisini incelemek.Gereç ve Yöntem: Eksüdatif yaşa bağlı maküla dejenerasyonu nedeniyle intravitreal ranibizumab enjeksiyon tedavisi alan 56 olgunun 61 gözü retrospektif olarak incelendi. Olguların enjeksiyondan sonra 1. gün, 1. ay, 3. ay ve 6. aydaki göz içi basınç değişimleri değerlendirildi. Bulgular: Olguların yaş ortalaması 72.6±7.5 idi. İntravitreal ranibizumab enjeksiyonu 61 göze uygulandı. Olguların takip süresi 6 aydı. Enjeksiyondan sonraki 1. günde olguların göz içi basınçları 21 mmHg, 3. ayda bir olguda > 21 mmHg idi. Olguların enjeksiyon öncesi ile 1. gün, 1, 3 ve 6. ayda ölçülen ortalama göz içi basınç değerleri karşılaştırıldığında istatiksel olarak anlamlı bir değişiklik olmadığı tespit edildi (p>0.05). Sonuç: Eksudatif yaşa bağlı maküla dejenerasyonu nedeniyle intravitreal ranibizumab enjeksiyonu göz içi basıncına etkisi olmamakla birlikte bazı olgularda göz içi basınç artışına neden olmaktadır.

🔖

Cite This Article

AYHAN, E. T., KAHRAMAN, H., İLHAN, N., DAĞLIOĞLU, M., COŞKUN, M., İLHAN, Ö., AYINTAP, E. (2014). Effect of Intravitreal Ranibizumab Injection on Introcular Pressure. Glokom Katarakt, Cilt: 9 - Sayı: 3, 173–176. https://ajindex.com/articles/208468

References (15)

Klein R, Peto T, Bird A, et al. The epidemiology of age-related macular degeneration. Am J Ophthalmol 2004;137:486-95.
Ferris FL III, Fine SL, Hyman L. Age-related macular degen- eration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984;102:1640-2.
Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. VEGF Inhibition Study in Ocular Neovascularization Clinical Tri- al Group. Pegaptanib for neovascular age-related macular degeneration.N Engl J Med 2004;351:2805-16.
Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31.
Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizum- ab treatment of choroidal neovascularization secondary to agerelated macular degeneration. Retina 2006;26:383-90.
Bakri SJ, McCannel CA, Edwards AO, et al. Persisent ocu- lar hypertension following intravitreal ranibizumab. Graefes Arch Clin Exp Ophthalmol 2008;246:955-8.
Brown DM, Campochiaro PA, Singh RP, et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Oph- thalmology 2010;117:1124-33.
Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evalu- ating ranibizumab plus prompt or deferred laser or triamcino- lone plus prompt laser for diabetic macular edema. Ophthal- mology 2010;117:1064-77.
Wehrli SJ, Tawse K, Levin MH, et al. A lack of delayed in- traocular pressure elevation in patients treated with intra- vitreal injection of bevacizumab and ranibizumab. Retina 2012;32:1295-301.
Kim JE, Mantravadi AV, Hur EY, et al. Short-term intraocu- lar pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am J Oph- thalmol 2008;146:930-3.
Wu H, Chen TC. The effects of intravitreal ophthalmic medications on intraocular pressure. Semin Ophthalmol 2009;24:100-5.
Yang CS, Chen MJ, Chou CK, et al. Refractory severe ocular hypertension after intravitreal triamcinolone acetonide injec- tion. Ophthalmologica 2005;219:413-5.
Demirçelik G, Önen M, Yazar Z, ve ark. İntravitreal beva- cizumab enjeksiyonu ile ilişkili göze ait ve sistemik kom- plikasyonlar. Ret-Vit 2009;17:269-72.
Rosenfeld PJ, Brown DM, Heier JS, et al. MARINA Study Group. Ranibizumab for neovascular age-related macular de- generation. N Engl J Med 2006;355:1419-31.
Brown DM, Kaiser PK, Michels M, et al. ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age- related macular degeneration.